eShowcase: Velos eResearch Version 7
New clinical trial software version provides direct data capture at investigator sites
New clinical trial software version provides direct data capture at investigator sites
Velos, Inc. (Fremont, CA) has released Velos eResearch Version 7 for increased features and functions for large investigative sites. Velos eResearch is a clinical trial management software system.
Velos eResearch Version 7 provides direct capture of clinical trial data, eliminating duplicate data entry. This in turn allows the systems used at the site to generate better or higher quality research data, and offer improved efficiency and productivity for investigators and sponsors.
Velos eResearch 7 uses Web 2.0 technology and system design. It features HL7 compliance, support for study administration, clinical data management, adverse event reporting, compliance with industry standards (including CFR Part 11), patient- and study-level architecture, and advanced security to large multi-institutional clinical studies.
Velos, Inc., (510) 739-4010, www.velos.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
